Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 306

[57] Li X, Liu YH, Zhang YP, Zhang S, Pu X, Gardner TA, et al. Fas ligand delivery by a
prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin
Cancer Res 2007;13:5463-73.
[58] Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional ther-
apy with TRAIL recombinant adenovirus. Mol Ther 2001;4:257-66.
[59] Lebedeva IV, Su ZZ, Sarkar D, Kitada S, Dent P, Waxman S, et al. Melanoma differentia-
tion associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells
by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer
Res 2003;63:8138-44.
[60] Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce
accumulation of MHC class II complexes on dendritic cells. Nature 1997;388:782-7.
[61] Simons JW, Mikhak B, Chang JF, DeMarzo A, Carducci MA, Lim M, et al. Induction of
immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradi-
ated autologous prostate tumor cells engineered to secrete granulocyte-macrophage col-
ony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-8.
[62] Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination
with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-
stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc
Natl Acad Sci USA 1993;90:3539-43.
[63] Simons J, Nelson W, Nemunaitis J, Centeno A, Dula E, Urba W, et al. Phase II trials of
a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refrac-
tory prostate cancer. Proc Am Soc Clin Oncol 2002;21. Abstract number 279.
[64] Small E, Higano C, Smith D, Corman J, Centero A, Streidle C, et al. A phase 2 study of
an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with
metastatic hormone-refractory prostate cancer (HRPC). Am Soc Clin Oncol 2005. Abstract
number 281.
[65] Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, et al. A phase I trial of a
recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate can-
cer. Clin Cancer Res 2000;6:1632-8.
[66] Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, et al. Phase I study
of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with
metastatic, androgen-independent prostate cancer. Prostate 2002;53:109-17.
[67] Steiner MS, Anthony CT, Lu Y, Holt JT. Antisense c-myc retroviral vector suppresses
established human prostate cancer. Hum Gene Ther 1998;9:747-55.
[68] Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, et al. Progression to
androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligode-
oxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res
1999;5:2891-8.
[69] Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate
attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for
prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63.
[70] Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, et al. Selective replica-
tion and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted
adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res
2000;60:6359-66.
[71] Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local
and systemic therapy of human prostate adenocarcinoma with the conditionally replicat-
ing herpes simplex virus vector G207. Hum Gene Ther 1999;13:2237-43.